Iodotyrosine derivatives and methods for producing same

Abstract

The present invention relates to compounds of general formula I TIFF2023551497000040.tif36170 A is an unbranched or branched alkyl group having 1 to 12 carbon atoms; -R 1 -OR 2 -group, -R 1 -Si(R 3 R 4 R 5 )-group, -R 1 -O-Si(R 3 R 4 R 5 )-group, -C(O)-OR 9 -Si(R 3 R 4 R 5 )-group, -CH(OR 6 )(OR 7 )-group, -R 1 -CH(OR 6 )(OR 7 )-group, -R 1 -OC(O)-OR 8 - selected from the group consisting of groups; SG is a protecting group; R 1 is a divalent hydrocarbon group having 1 to 12 carbon atoms; R 2 is a monovalent hydrocarbon group having 1 to 12 carbon atoms; R 3 , R 4 and R 5 are each independently a monovalent hydrocarbon group having 1 to 12 carbon atoms; R 6 and R 7 are each independently a monovalent hydrocarbon group having 1 to 12 carbon atoms; R 8 is a monovalent hydrocarbon group having 1 to 12 carbon atoms R 9 is a divalent hydrocarbon group having 1 to 12 carbon atoms.

Description

[Technical Field]

[0001] The present invention relates to iodotyrosine derivatives, particularly Fmoc-3-iodo-tyrosine derivatives and Boc-3-iodo-tyrosine derivatives, methods for producing iodotyrosine derivatives, particularly Fmoc-3-iodo-tyrosine derivatives and Boc-3-iodo-tyrosine derivatives, and the use of iodotyrosine derivatives, particularly Fmoc-3-iodo-tyrosine derivatives and Boc-3-iodo-tyrosine derivatives, in peptide synthesis. [Background technology]

[0002] Modification of peptides with 3-iodotyrosine (D / L) essentially serves to positively influence the properties of peptides containing iodotyrosine. In most cases, iodotyrosine is primarily introduced at the N-terminus of peptides or small molecules [4] (Non-Patent Document 1). Because iodotyrosine is lipophilic, its binding properties, often resulting in improved receptor affinity, are improved. Examples of peptides or peptide compounds containing iodotyrosine include the theranostic peptides Pentixather / Pentixather / Pentixafor [5] (Non-Patent Document 2), HA-Dotatate [6] (Non-Patent Document 3), or PSMA I&T [7] (Non-Patent Document 4). Furthermore, the replacement of tyrosine with iodotyrosine leads to improved hormonal properties [8] (Non-Patent Document 5).

[0003] Iodotyrosine is often introduced using the commercially available building blocks Fmoc-3-iodo-L-tyrosine, Fmoc-3-iodo-D-tyrosine, Boc-3-iodo-D-tyrosine, or Boc-3-iodo-L-tyrosine. The term "Fmoc" refers to the fluorenylmethyloxycarbonyl protecting group. The term "Boc" refers to the tert-butyloxycarbonyl protecting group. However, the use of Fmoc-3-iodo-L-tyrosine, Fmoc-3-iodo-D-tyrosine, Boc-3-iodo-D-tyrosine, or Boc-3-iodo-L-tyrosine can be accompanied by undesirable side reactions, as its hydroxy functionality at the para position is sufficiently nucleophilic to be acylated by a C-terminal activated amino acid. This often leads to the loss of the amino acid, which is no longer available for coupling. In this context, coupling with Fmoc-3-iodo-L-tyrosine, Fmoc-3-iodo-D-tyrosine, Boc-3-iodo-D-tyrosine or Boc-3-iodo-L-tyrosine can result from the high reactivity of the nucleophilic hydroxy functionality of tyrosine and has proven impractical when there is little or no turnover during this reaction step.

[0004] One way to overcome this drawback is to iodinate tyrosine in the final peptide product. This method usually yields two different products consisting of monoiodinated and diiodinated tyrosine residues [9] (Non-Patent Document 6). Both products must be separated by reversed-phase chromatography, making industrial application difficult. Furthermore, this method is not suitable when there are more than one tyrosine unit in the peptide. Furthermore, this method is not suitable for industrial application due to the obvious limitations on the synthesis scale. Furthermore, it requires the separation of the starting material.

[0005] Cobb et al.

[10] (Non-Patent Document 7) proposed the direct iodination of fully protected Fmoc-Tyr(tBu)-OH in the presence of AgSO in methanol, primarily to produce Fmoc-3-iodo-Tyr(tBu)-OMe, followed by saponification. This method is considered unsuitable for the larger scale required for industrialization. Amedio et al.

[11] (Non-Patent Document 8) presented the use of Boc-3-iodo-Tyr(PMB)-OH. In another example, Kiyoyuki et al.

[12] (Non-Patent Document 9) used Boc-3-iodo-Tyr(Boc)-OH for the synthesis of cyclic peptides. Both protected iodotyrosine derivatives are exclusively suitable for Boc chemistry. Martiny et al. synthesized Fmoc-3-iodo-Tyr(TBDMS)-OH and demonstrated its suitability for the introduction of iodinated tyrosines into peptides using Fmoc / tBu chemistry

[13] (Non-Patent Document 10). A drawback of this particular compound is its sensitivity to (weak) acids (e.g., hexafluoroisopropanol (HFIP)). This sensitivity can result in the inability to cleave fully protected peptides from the resin (e.g., with HFIP). The term "tBu" refers to the protecting group "tert-butyl," "Me" refers to methyl, "boc" refers to the protecting group tert-butoxycarbonyl, "PMB" refers to the protecting group p-methoxybenzyl, and "TBDMS" refers to the protecting group tert-butyldimethylsilyl. [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] Assoian, RK, et al., Iodotyrosylation of peptides using tertiary-butyloxycarbonyl-l-[125I]iodotyrosine N-hydroxysuccinimide ester. Analytical Biochemistry, 1980. 103(1): p. 70-76. [Non-patent document 2] Schottelius, M., et al., [(177)Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. Theranostics, 2017. 7(9): p. 2350-2362. [Non-Patent Document 3] Brogsitter, C., et al., Twins in spirit part II: DOTATATE and high-affinity DOTATATE-the clinical experience. European journal of nuclear medicine and molecular imaging, 2014. 41. [Non-Patent Document 4] Weineisen, M., et al., 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J Nucl Med, 2015. 56(8): p. 1169-76. [Non-Patent Document 5] A, W.M., IODINATED INSULIN ANALOGUES WITH FORESHORTENED SIGNALING. 14.12.2016. [Non-Patent Document 6] Schottelius, M., et al., An optimized strategy for the mild and efficient solution phase iodination of tyrosine residues in bioactive peptides. Tetrahedron Letters, 2015. 56(47): p. 6602-6605. [Non-Patent Document 7] Steer, AM, et al., A direct route for the preparation of Fmoc / OtBu protected iodotyrosine. Tetrahedron Letters, 2018. 59(27): p. 2644-2646. [Non-patent document 8] White, JD and JC Amedio, Total synthesis of geodiamolide A, a novel cyclodepsipeptide of marine origin. The Journal of Organic Chemistry, 1989. 54(4): p. 736-738. [Non-Patent Document 9] Ishiwata, H., et al., Total Synthesis of Doliculide, a Potent Cytotoxic Cyclodepsipeptide from the Japanese Sea Hare Dolabella auricularia. The Journal of Organic Chemistry, 1994. 59(17): p. 4712-4713. [Non-Patent Document 10] Pedersen, MHF and L. Martiny, Homogeneous deuteriodeiodination of iodinated tyrosine in angiotensin-I using synthesized triethyl[2H]silane and Pd(0). 2011. 54(4): p. 191-195. Summary of the Invention [Problem to be solved by the invention]

[0007] The object of the present invention is to overcome the drawbacks of the prior art. It is necessary to provide iodotyrosine derivatives, in particular Fmoc-3-iodotyrosine and Boc-3-iodotyrosine derivatives, which do not prevent the modification of peptides by introducing iodotyrosine units without the side reactions described and without cleavage of the peptides thus modified when fully protected by the resin. [Means for solving the problem]

[0008] This problem is solved by the features of claims 1, 9 and 12. Useful embodiments of the invention are provided by the features of the dependent claims.

[0009] According to the present invention, there is provided a compound of general formula I: [ka] During the ceremony A is an unbranched or branched alkyl group having 1 to 12 carbon atoms; -R 1 -OR 2 -group, -R 1 -Si(R 3 R 4 R 5 )-group, -R 1 -O-Si(R 3 R 4 R 5 )-group, -C(O)-OR 9 -Si(R 3 R 4 R 5 )-group, -CH(OR 6 )(OR 7 )-group, -R 1 -CH(OR 6 )(OR 7 )-group, -R 1 -OC(O)-OR 8 - selected from the group consisting of groups; SG is a protecting group; R 1 is a divalent hydrocarbon group having 1 to 12 carbon atoms; R 2is a monovalent hydrocarbon group having 1 to 12 carbon atoms; R 3 , R 4 and R 5 are each independently a monovalent hydrocarbon group having 1 to 12 carbon atoms; R 6 and R 7 are each independently a monovalent hydrocarbon group having 1 to 12 carbon atoms; R 8 is a monovalent hydrocarbon group having 1 to 12 carbon atoms R 9 is a divalent hydrocarbon group having 1 to 12 carbon atoms.

[0010] The protecting group SG is preferably selected from the group consisting of fluorenylmethyloxycarbonyl (Fmoc), tert-butoxycarbonyl (Boc) and benzyloxycarbonyl. More preferably, the protecting group SG is fluorenylmethyloxycarbonyl (Fmoc) or tert-butoxycarbonyl. The protecting group SG is particularly preferably fluorenylmethyloxycarbonyl (Fmoc). The protecting group SG serves to protect the amino function of the tyrosine moiety. The compound of general formula I is hereinafter also referred to as SG-iodo-tyrosine.

[0011] A compound of general formula I in which SG is a fluorenylmethyloxycarbonyl group (Fmoc) is a compound of general formula Ia, and a compound of general formula I in which SG is a tert-butoxycarbonyl group (Boc) is a compound of general formula Ib: [ka]

[0012] The compound of general formula Ia is also referred to hereinafter as Fmoc-iodo-tyrosine. The compound of general formula Ib is also referred to hereinafter as Boc-iodo-tyrosine.

[0013] The compounds of general formula I according to the present invention include both each enantiomer itself and a mixture of these enantiomers. Thus, the tyrosine units of the compounds of general formula I can exist in the D-configuration, the L-configuration, or a mixture of the D- and L-configurations. The term "D / L" refers to a compound in the D-configuration, a compound in the L-configuration, or a mixture of the D- and L-configurations.

[0014] The compounds of general formula I of the present invention have an iodine atom attached to the phenyl group of the tyrosine unit.

[0015] The compounds of the present invention allow the incorporation of SG-3-iodo-D-tyrosine (A)-OH or SG-3-iodo-L-tyrosine (A)-OH into peptides. Protection of the phenolic hydroxy group by protecting the A group prevents undesired side reactions associated with the unprotected hydroxy functionality in the prior art. Therefore, the A unit prevents acylation with an activated amino acid at the C-terminus, preventing loss of the amino acid. Furthermore, because the phenolic hydroxy function is protected by the A moiety, the difficult coupling with SG-3-iodo-D-tyrosine (A)-OH or SG-3-iodo-L-tyrosine (A)-OH is now possible. In particular, the present invention allows the incorporation of Fmoc-3-iodo-D-tyrosine (A)-OH or Fmoc-3-iodo-L-tyrosine (A)-OH into peptides. Alternatively, Boc-3-iodo-D-tyrosine (A)-OH or Boc-3-iodo-L-tyrosine (A)-OH can be introduced into a peptide. The notation "(A)-OH" is intended to indicate that the phenolic hydroxy group of the tyrosine moiety is protected by protecting group A, but the hydroxy group of the carboxy group is not. After introducing SG-3-iodo-D-tyrosine (A)-OH or SG-3-iodo-L-tyrosine (A)-OH into a peptide, the protecting group A can be cleaved.

[0016] It can be shown that the compound of general formula I is a compound of general formula IA [ka] wherein A is defined in claim 1. Compounds of general formula IA correspond to compounds of general formula I, except that the iodine atom is in position 3. Compounds of general formula IA in which SG is a fluorenylmethyloxycarbonyl group (Fmoc) are compounds of general formula Ia-A, and compounds of general formula I in which SG is a tert-butoxycarbonyl group (Boc) are compounds of general formula Ib-A: [ka]

[0017] The unit A is a protecting group for protecting the phenolic hydroxy group of SG-iodo-tyrosine. Preferably, the unit A is an ether group, a silyl ether group, an acetal group, or a carbonate group. In the case of Fmoc-iodo-tyrosine, the unit A is preferably selected so as to be compatible with the Fmoc / tBu strategy applied to non-iodinated Fmoc-D / L-tyrosine(tBu)-OH. In Fmoc-D / L-tyrosine(tBu)-OH, the phenolic hydroxy function is protected by a tert-butyl group (tBu). The unit A is also selected so that the compound according to the present invention can be used on a production scale.

[0018] R 1 is preferably an unbranched alkylene group having 1 to 6 methylene units. 1 is methylene, ethylene or n-propylene.

[0019] R 2 is preferably an unbranched or branched alkyl group having 1 to 12 carbon atoms or an aryl group, and is preferably an unbranched or branched alkyl group having 1 to 12 carbon atoms.

[0020] Preferably, R 3 , R 4 and R 5 are each independently an unbranched or branched alkyl group or an aryl group having 1 to 2 carbon atoms.

[0021] Preferably, R 6 and R 7 are each independently an unbranched or branched alkyl group having 1 to 2 carbon atoms, or an aryl group.

[0022] R 8 is preferably an unbranched or branched alkyl group having 1 to 12 carbon atoms, or an aryl group, with an unbranched or branched alkyl group having 1 to 12 carbon atoms being preferred.

[0023] R 9 is preferably an unbranched alkylene group having 1 to 6 methylene units. 1 is methylene, ethylene, propylene or butylene.

[0024] The unit A is an unbranched or branched alkyl group having 1 to 12 carbon atoms, -R 1 -OR 2 -group, -R 1 -Si(R 3 R 4 R 5 )-group, and -C(O)-OR 9 -Si(R 3 R 4 R 5 )-groups. 1 -OR 2 -group, -R 1 -Si(R 3 R 4 R 5 )-group, -R 1 -O-Si(R 3 R 4 R 5 )-group, -C(O)-OR 9 -Si(R 3 R 4 R 5 )-group, -CH(OR 6 )(OR 7 )-group, -R 1 -CH(OR 6 )(OR 7 )-group, -R1 -OC(O)-OR 8 - groups may also be provided. It can further be provided that unit A is selected from the group consisting of: an alkyl group having 1 to 6 carbon atoms; R 1 is an alkylene group having 1 to 6 carbon atoms, and R 2 -R is an unbranched or branched alkyl group having 1 to 6 carbon atoms 1 -OR 2 Base; R 1 is an alkylene group having 1 to 6 carbon atoms, and R 3 , R 4 and R 5 each independently represents an unbranched or branched alkyl group having 1 to 6 carbon atoms, or an aryl group; 1 -Si(R 3 R 4 R 5 )-group; and R 9 is an alkylene group having 1 to 6 carbon atoms, and R 3 , R 4 and R 5 are each independently an unbranched or branched alkyl group having 1 to 6 carbon atoms, or an aryl group, 9 -Si(R 3 R 4 R 5 )-group.

[0025] Compounds of general formula I can be provided, wherein: where A is -R 1 -OR 2 -group, -R 1 -Si(R 3 R 4 R 5 )-group, -R 1 -O-Si(R 3 R 4 R 5 )-group, -C(O)-OR 9 -Si(R 3 R 4 R5 )-group, -CH(OR 6 )(OR 7 )-group, -R 1 -CH(OR 6 )(OR 7 )-group, -R 1 -OC(O)-OR 8 - selected from the group consisting of groups; SG is a protecting group; R 1 is a divalent hydrocarbon group having 1 to 12 carbon atoms; R 2 is a monovalent hydrocarbon group having 1 to 12 carbon atoms; R 3 , R 4 and R 5 are each independently a monovalent hydrocarbon group having 1 to 12 carbon atoms; R 6 and R 7 are each independently a monovalent hydrocarbon group having 1 to 12 carbon atoms; R 8 is a monovalent hydrocarbon group having 1 to 12 carbon atoms R 9 is a divalent hydrocarbon group having 1 to 12 carbon atoms.

[0026] It can further be provided that unit A is selected from the group consisting of: R 1 is an alkylene group having 1 to 6 carbon atoms, and R 2 -R is an unbranched or branched alkyl group having 1 to 6 carbon atoms 1 -OR 2 Base; R 1 is an alkylene group having 1 to 6 carbon atoms, and R 3 , R 4 and R 5 are each independently an unbranched or branched alkyl group having 1 to 6 carbon atoms, or an aryl group; 1 -Si(R 3 R 4 R 5 )-group R 9 is an alkylene group having 1 to 6 carbon atoms, and R 3 , R 4 and R 5 are each independently an unbranched or branched alkyl group having 1 to 6 carbon atoms, or an aryl group, C(O)-OR 9 -Si(R 3 R 4 R 5 )-group.

[0027] Suitable examples of compounds of general formula Ia-A are: (i) 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-iodo-4-(methoxymethoxy)phenyl)propionic acid, which is also designated Fmoc-D / L-Tyr(MOM)-OH, with Fmoc-D-Tyr(MOM)-OH being particularly preferred; (ii) 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-iodo-4-(((2-(trimethylsilyl)ethoxy)carbonyl)oxy)phenyl)propionic acid, which is also designated Fmoc-D / L-Tyr(TEOC)-OH, with Fmoc-D-Tyr(TEOC)-OH being particularly preferred; (iii) 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(2-(tert-butyldiphenylsilyl)ethoxy)-3-iodophenyl)propionic acid, which is also designated Fmoc-D / L-Tyr(TBDPSE)-OH, with Fmoc-D-Tyr(TBDPSE)-OH being particularly preferred; (iv) 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(tert-butoxy)-3-iodophenyl)propionic acid, which is also designated Fmoc-D / L-Tyr(tBu)-OH, with Fmoc-D-Tyr(tBu)-OH being particularly preferred.

[0028] Suitable examples of compounds of general formula Ib-A are: (i) 2-((tert-butoxycarbonyl)amino)-3-(3-iodo-4-(methoxymethoxy)phenyl)propionic acid, which is also designated as Boc-D / L-Tyr(MOM)-OH, with Boc-D-(MOM)-OH being preferred; (ii) 2-((tert-butoxycarbonyl)amino)-3-(3-iodo-4-(((2-(trimethylsilyl)ethoxy)carbonyl)oxy)phenyl)propionic acid, which is also designated Boc-D / L-Tyr(TEOC)-OH, with Boc-D-Tyr(TEOC)-OH being preferred; (iii) 2-((tert-butoxycarbonyl)amino)-3-(4-(2-(tert-butyldiphenylsilyl)ethoxy)-3-iodophenyl)propionic acid, which is also designated Boc-D / L-Tyr(TBDPSE)-OH, with Boc-D-Tyr(TBDPSE)-OH being preferred; (iv) 2-((tert-butoxycarbonyl)amino)-3-(4-(tert-butoxy)-3-iodophenyl)propionic acid, which is also designated Boc-D / L-Tyr(tBu)-OH, with Boc-D-Tyr(tBu)-OH being preferred.

[0029] The present invention also provides a method for preparing a compound of general formula I according to the invention, for this purpose, comprising reacting a compound of general formula II with a compound of general formula XA to give a compound of general formula I, [ka] wherein SG has the meaning given in relation to general formula I, X is halogen or ammonium, and A has the meaning given in relation to general formula I, [ka] wherein SG and A have the meanings given in relation to formula I. Protecting group A is introduced into a compound of general formula II by compound XA. When SG is Fmoc in a compound of general formula II, the compound is Fmoc-iodo-D / L-tyrosine, which is systematically defined as 2-(((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-hydroxy-iodophenyl)propionic acid. The compound of general formula II is preferably Fmoc-iodo-D-tyrosine. When SG is Boc in a compound of general formula II, the compound is Boc-iodo-D / L-tyrosine, which is systematically defined as 2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-iodophenyl)propionic acid, with Boc-iodo-D-tyrosine being preferred.

[0030] A particularly preferred compound of general formula II is Fmoc-3-iodo-D / L-tyrosine, which is systematically identified as 2-(((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-hydroxy-3-iodophenyl)propionic acid. In this compound, the phenolic iodine atom is at the 3-position. Fmoc-3-iodo-D-tyrosine is particularly preferred. Another preferred compound of general formula II is Boc-3-iodo-D / L-tyrosine, which is systematically named 2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-3-iodophenyl)propionic acid. In this compound, the phenolic iodine atom is at the 3-position. Boc-3-iodo-D-tyrosine is particularly preferred.

[0031] Compounds of general formula II can be prepared from compounds of general formula IV. [ka] The amine function of the compound of general formula IV is protected by introducing a protecting group SG. For this purpose, the compound of general formula IV can be reacted with, for example, a 9-fluorenylmethoxycarbonyl reagent or a tert-butoxycarbonyl reagent. The 9-fluorenylmethoxycarbonyl compound can be, for example, (9-fluorenylmethoxycarbonyloxy)succinimide (Fmoc-OSu). The tert-butoxycarbonyl reagent can be, for example, di-t-butyl dicarbonate (BocO). The compound of general formula IV is D / L-iodotyrosine, with D-iodotyrosine being preferred.

[0032] A compound of general formula II can be reacted with a compound of general formula XA to give a compound of general formula III, [ka] The compound of general formula III is then reacted to convert it into a compound of general formula I. Scheme 1 illustrates the inventive preparation of a compound of general formula I according to the invention from a compound of general formula II. [ka] Scheme 1a illustrates the preparation of a compound of general formula Ia according to the present invention from a compound of general formula IIa. Compound IIa is a compound of general formula II where SG is Fmoc. The process shown in Scheme 1a is one embodiment of the process shown in Scheme 1. [ka] Scheme 2 illustrates the inventive preparation of compounds of general formula Ia-A according to the invention from 3-iodo-D / L-tyrosine. The process shown in Scheme 2 is a preferred embodiment of the process shown in Scheme 1a. [ka]

[0033] Step (a) shown in Scheme 1 provides for the conversion of a compound of general formula IV to a compound of general formula II. In this process, a protecting group that protects the amine function is introduced at the N-terminus of the compound of general formula IV. For this purpose, the compound of general formula IV can be reacted with, for example, (9-fluorenylmethoxycarbonyloxy)succinimide (Fmoc-OSu) (see Scheme 1a) or di-tert-butyl dicarbonate (BocO). The compound of general formula II corresponds to the compound of general formula IV, except that the N-terminus of the compound of general formula IV is protected by the protecting group SG. Ambient temperature means a temperature in the range of 18-25°C.

[0034] When Fmoc is introduced as the protecting group SG in step (a) of Scheme 1, step (a) can be carried out under a protective gas (inert gas), for example argon, at ambient pressure and temperature. To introduce Fmoc as the protecting group SG, step (a) is preferably carried out in a mixture of aqueous sodium carbonate and 1,4-dioxane.

[0035] When Boc is introduced as the protecting group SG in step (a) of Scheme 1, step (a) can be carried out at ambient pressure and temperature. Protective gas is not required. In this case, step (a) is preferably carried out in a mixture of water, tetrahydrofuran, and triethylamine.

[0036] Step (b) of the process shown in Scheme 1 provides for the conversion of a compound of general formula II to a compound of general formula III. In this process, the C-terminal hydroxyl group and the phenolic hydroxyl group of the compound of general formula II are protected with the unit A. To this end, the compound of general formula II is reacted with compound XA. This reaction can occur in an aprotic solvent, such as dichloromethane (DCM), in the presence of an auxiliary base, such as diisopropylethylamine (Huenig's base, DIPEA), and a phase transfer catalyst, such as tetrabutylammonium chloride (TBACl). The reaction can be carried out at a temperature ranging from 0°C to ambient temperature. It can be carried out under ambient pressure and a protective gas, such as an argon atmosphere. The compound of general formula III corresponds to the compound of general formula II, except that the C-terminal hydroxyl group and the phenolic hydroxyl group of the compound of general formula II are protected with the unit A.

[0037] Step (c) shown in Scheme 1 provides for the conversion of a compound of general formula III to a compound of general formula I. In this process, unit A protecting the C-terminal hydroxy group of the compound of general formula III is cleaved, while unit A protecting the phenolic hydroxy group is retained. The cleavage occurs in a basic range, for example, in a pyridine / water mixture. The reaction can be carried out in a temperature range between 0°C and ambient temperature. It can be carried out at ambient pressure. Protective gas is not required. The compound of general formula I corresponds to the compound of general formula III, except for the presence of a hydroxy group at the C-terminus of the compound of general formula I.

[0038] Further details of the process according to the invention have already been described in connection with the compounds of general formula I according to the invention, reference is made to those descriptions.

[0039] The present invention provides the use of a compound of general formula I according to the present invention for the preparation of a peptide. The prepared peptide has at least one iodo-tyrosine unit. The prepared peptide can correspond to a known peptide, except that at least one, preferably exactly one, tyrosine unit is replaced with a 3-iodo-tyrosine unit. The 3-iodo-tyrosine unit can be prepared by reacting a compound of general formula I with an amino acid or amino acid sequence to obtain a peptide. Peptides can be prepared by known synthetic methods, for example, by Merrifield synthesis. Routes to peptide synthesis are described by Robert Bruce Merrifield, "Solid Phase Peptide Synthesis," Journal of the American Chemical Society, Volume 85, Issue 14, pp. 2149-2154. After preparation of the peptide, unit A derived from the compound of general formula I is cleaved, thereby obtaining a peptide having a 3-iodo-tyrosine unit whose phenolic OH group is unprotected.

[0040] Scheme 3 illustrates the preparation of peptides of general formula V having an iodo-tyrosine unit using compounds of general formula I. [ka] Scheme 3a illustrates the preparation of peptides of general formula Va having an iodo-tyrosine unit using compounds of general formula Ia. Peptides of general formula Va are peptides of general formula V in which SG is Fmoc. [ka] The protecting group SG can then be cleaved, thereby converting compounds of general formula V to compounds of general formula VI, as shown in Scheme 4 and Scheme 4a. [ka] [ka] If the iodo-tyrosine unit is not the terminal unit of the peptide, additional amino acids can be attached to the N-terminus of compounds of general formula VI to give compounds of general formula VII as shown in Scheme 5. [ka] One or more additional amino acids can be further attached to the amino acid, thereby obtaining a peptide of general formula VIII: [ka] where A has the meaning given in relation to the compounds of general formula I, and R 10 is hydrogen or one or more amino acid units, and R 11 is hydrogen or one or more amino acid units, with the proviso that R 10 If is hydrogen, then R 11 is not hydrogen, but R 11 If is hydrogen, then R 10 is not hydrogen. The amino acid unit has an NH group or NR 12 - group, where R 12 is a methyl group.

[0041] Compounds of general formula VIII can be converted to peptides of general formula IX by cleaving unit A as shown in Scheme 6. [ka] The cleavage of unit A is carried out in the acidic range, for example, during the overall deprotection of the peptide. An aqueous solution of trifluoroacetic acid (TFA), for example, a 95% TFA solution, is preferably used for the overall deprotection of the peptide. The reaction can be carried out at a temperature range between 0°C and ambient temperature. It can be carried out at ambient pressure. Protective gas is not required. Compounds of general formula IX correspond to compounds of general formula VIII, except that unit A is cleaved to give a hydroxy group.

[0042] The term "alkyl," unless otherwise specified, refers to a monovalent saturated aliphatic hydrocarbon group having a branched or unbranched carbon chain having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, and more preferably 1 to 6 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl, n-hexyl, octyl, dodecyl, and the like.

[0043] The term "alkylene," unless otherwise specified, refers to a divalent saturated aliphatic hydrocarbon group having a branched or unbranched carbon chain having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, and more preferably 1 to 6 carbon atoms. Examples of alkylene groups include, but are not limited to, methylene, ethylene, propylene, butylene, and the like.

[0044] The term "aryl," unless otherwise specified, refers to a cyclic aromatic hydrocarbon group consisting of a monocyclic, bicyclic, or tricyclic aromatic ring system having 5 to 18 ring atoms, preferably 5 or 6 ring atoms. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, phenanthryl, fluorenyl, indenyl, azulenyl, biphenyl, methylenediphenyl, and the like, including partially hydrogenated derivatives thereof. Unless otherwise specified, aryl groups can be monovalent or polyvalent, e.g., monovalent or divalent.

[0045] The invention is explained in more detail below using exemplary embodiments that are not intended to limit the invention. [Example]

[0046] Examples of compounds according to the present invention are shown in Table 1. Compounds 1D, 2D, 3D and 4D have the R configuration and are derivatives of D-tyrosine. Compounds 1L, 2L, 3L and 4L have the S configuration and are derivatives of L-tyrosine.

[0047] [Table 1] TIFF0007818005000020.tif235170

[0048] Several compounds in Table 1 are exemplary compounds of Formula I and Formula Ia. Compounds 1D and 1L are compounds where A is -R 1 -OR 2 - group, and R 1 is a methylene group, and R 2 Compounds 2D and 2L are compounds of formula Ia where A is -R 1 -Si(R 3 R 4 R 5 )-group, and R 1 is -CH2-CH2- and R 3 , R 4 and R 5 Compounds 3D and 3L are compounds of formula Ia in which A is -R 1 -Si(R 3 R 4 R 5 )-group, and R 1 is -CH2-CH2- and R 3 , and R 4 are compounds of formula Ia where A is a tert-butyl group. Compounds 4D and 4L are compounds of formula Ia where A is a tert-butyl group.

[0049] Further examples of compounds according to the invention are shown in Table 1a. Compounds 5D, 6D, 7D and 8D have the R configuration and are derivatives of D-tyrosine. Compounds 5L, 6L, 7L and 8L have the S configuration and are derivatives of L-tyrosine.

[0050] [Table 1a] TIFF0007818005000022.tif222170

[0051] The compounds listed in Table 1a are exemplary compounds of general formula I and general formula Ib. Compounds 5D and 5L are -R 1 -OR2 - group, and R 1 is a methylene group, and R 2 Compounds 6D and 6L are compounds of formula Ib in which A is -R 1 -Si(R 3 R 4 R 5 )-group, and R 1 is -CH2-CH2- and R 3 , R 4 and R 5 Compounds 7D and 7L are compounds of formula Ib in which A is -R 1 -Si(R 3 R 4 R 5 )-group, and R 1 is -CH2-CH2-, R 3 and R 4 are compounds of formula Ib where A is a tert-butyl group. Compounds 8D and 8L are compounds of formula Ib where A is a tert-butyl group.

[0052] The abbreviations used in the title have the following meanings: Boc t-butoxycarbonyl Fmoc 9-Fluorenylmethyloxycarbonyl MOM methoxymethyl OH hydroxy group of a carboxyl unit TBDPSE t-butyldiphenylsilylethyl TEOC 2-(trimethylsilyl)ethoxycarbonyl D-Tyr D-Tyrosine L-Tyr L-Tyrosine The present invention includes the following items. [Item 1] Compounds of general formula I [ka] During the ceremony A is an unbranched or branched alkyl group having 1 to 12 carbon atoms; -R 1 -OR2 -group, -R 1 -Si(R 3 R 4 R 5 )-group, -R 1 -O-Si(R 3 R 4 R 5 )-group, -C(O)-OR 9 -Si(R 3 R 4 R 5 )-group, -CH(OR 6 )(OR 7 )-group, -R 1 -CH(OR 6 )(OR 7 )-group, -R 1 -OC(O)-OR 8 - selected from the group consisting of groups; SG is a protecting group; R 1 is a divalent hydrocarbon group having 1 to 12 carbon atoms; R 2 is a monovalent hydrocarbon group having 1 to 12 carbon atoms; R 3 、R 4 and R 5 are each independently a monovalent hydrocarbon group having 1 to 12 carbon atoms; R 6 and R 7 are each independently a monovalent hydrocarbon group having 1 to 12 carbon atoms; R 8 is a monovalent hydrocarbon group having 1 to 12 carbon atoms R 9 is a divalent hydrocarbon group having 1 to 12 carbon atoms. [Item 2] Compounds according to item 1, characterized in that they are compounds of general formula IA,

change

change

change

change

change

change

change

[0053] Example 1 Synthesis of Fmoc-3-iodo-D-Tyr(MOM)-OH (1D) The synthesis of Fmoc-3-iodo-D-Tyr(MOM)-OH was carried out as depicted in Scheme B1: [ka] In step (a), (R)-2-amino-3-(4-hydroxy-3-iodophenyl)propionic acid 11 (also referred to as 3-iodo-D-tyrosine or 3-iodo-D-Tyr-OH) was reacted with N-(9-fluorenylmethoxycarbonyloxy)-succinimide (Fmoc-OSu) to give (R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-hydroxy-3-iodophenyl)propionic acid 12 (also referred to as Fmoc-3-iodo-D-Tyr-OH). The reaction took place in a mixture of aqueous sodium carbonate and 1,4-dioxane. In step (b), compound 12 was reacted with methoxymethyl bromide (CH3-O-CH2-Br) to give methoxymethyl-(R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-iodo-4-(methoxymethoxy)phenyl)propanoate 13 (also referred to as Fmoc-3-iodo-D-Tyr(MOM)-OMOM). The reaction occurred in dichloromethane (DCM) in the presence of diisopropylethylamine (DIPEA) and tetrabutylammonium chloride (TBACl). In step (c), compound 13 was then converted to the target compound 1D. The reaction occurred in a mixture of tetrahydrofuran (THF), water, and pyridine.

[0054] The resulting compounds were analyzed by both HPLC and LC-MS analysis.

[0055] a) Synthesis of Fmoc-3-iodo-D-Tyr-OH (12) 3-Iodo-D-Tyr-OH 11 (5 g, 16.28 mmol) was suspended in 50 mL of aqueous NaCO (1.726 g, 16.28 mmol) under an argon atmosphere. 10 mL of dioxane was added, and the yellow solution was cooled in an ice-water bath. Fmoc-OSu (5.492 g, 16.28 mmol) dissolved in 50 mL of 1,4-dioxane was added dropwise via a dropping funnel under an argon atmosphere. After the addition, the reaction mixture was stirred in an ice-water bath for 1 h and then at room temperature. After 17 h, thin-layer chromatography (eluent: DCM / methanol (MeOH), 9:1) showed complete conversion to the desired product, Fmoc-3-iodo-D-Tyr-OH. 100 mL of HO was added, and the mixture was cooled in an ice-water bath. 30% HCl (approximately 4 mL) was added until the pH reached 2–3. The mixture was extracted with ethyl acetate (3 x 150 mL), and the combined organic phases were washed with HO (2 x 150 mL) and brine (1 x 150 mL), dried over NaSO, and filtered (filter pore size 4). The solvent was removed by rotary evaporation, and the residue was dried under high vacuum. Yield: 9.5 g (110%, quantitative) of a white foamy solid crude product was used in the next step without purification.

[0056] HPLC:t R = 7.26 min. LC-MS:t R =12.57 min, m / z=530.05 [M+H] + ,1059.16[2M+H] + . 1 H NMR (DMSO-d 6 ,500MHz):12.70(br,1H),10.12(s,1H),7.88(m,2H),7.72-7.60(m,4H),7.43-7.39(m,2H),7.34-7.28(m, 2H),7.09(m,1H),6.79(m,1H),4.21-4.18(m,3H),4.10-5.05(m,1H),2.97-2.93(m,1H),2.75-2.70(m,1H).

[0057] b) Synthesis of Fmoc-3-iodo-D-Tyr(MOM)-OMOM (13) Fmoc-3-iodo-D-Tyr-OH 12 (9.5 g, i.e., 8.62 g, 16.28 mmol ≡ 100%) was suspended in 120 mL of DCM (anhydrous) under an argon atmosphere. DIPEA (5.673 mL, 32.57 mmol, 2 equiv.) was added, and after stirring at room temperature for 10 min, a yellow solution resulted. TBACl (453 mg, 1.628 mmol, 0.1 equiv.) was added, and the mixture was cooled in an ice-water bath. Methoxymethyl bromide (MOMBr) (2.658 mL, 32.57 mmol, 2 equiv.) diluted with 30 mL of DCM (anhydrous) was added dropwise via a dropping funnel under an argon atmosphere (gas evolution). After the addition, the reaction mixture was stirred under ice cooling. After 1 h, stirring was continued at room temperature for an additional 18 h. Analysis with DCM / MeOH (50:1) indicated complete conversion. 100 mL of H2O was added and the mixture was vigorously stirred at room temperature. After 1 h, the phases were separated in a separatory funnel. The aqueous phase was extracted several times with 150 mL of DCM each time. The combined organic phases were washed with 1 N HCl (2 x 150 mL) and brine (150 mL), dried over Na2SO4, and filtered (filter pore size 4). The solvent was removed under reduced pressure, and the residue was dried under high vacuum. Yield: 11 g (109%, quantitative) of the crude white foamy solid was used in the next step without purification.

[0058] HPLC:t R =8.97 min. LC-MS:t R =14.76 min, m / z=618.12 [M+H] + ,1235.32[2M+H] + .

[0059] c) Synthesis of Fmoc-3-iodo-D-Tyr(MOM)-OH (1D) Fmoc-3-iodo-D-Tyr(MOM)-OMOM 13 was dissolved in 140 mL of THF(pa). A mixture of 400 mL of HO and 10 mL of pyridine was added with stirring. Approximately 100 mL of THF(pa) was added until a clear mixture was formed. With vigorous stirring, the mixture was heated to reflux in an oil bath (70 °C). After 64 h, HPLC (214 nm) showed complete conversion of the starting material to the product Fmoc-3-iodo-D-Tyr(MOM)-OH (tR = 8.96 min). The solvent (THF) was evaporated under reduced pressure. To this mixture, approximately 120 mL of 2 N HCl was added under ice-cooling. The pH of the solution was between pH 4 and pH 5. The mixture was extracted with DCM (3 x 150 mL), and the combined organic phases were washed with 0.5 N HCl (2 x 150 mL) and saturated brine (150 mL), dried over Na2SO4, and filtered. The solvent was evaporated under reduced pressure, and the residue was dried under high vacuum. Yield: 9.7 g (104%, quantitative) of the crude white foam solid was purified by column chromatography (yield: 4.6 g, purity by HPLC (214 nm): >95%).

[0060] m / z=574.11[M+H]+,1147.26[2M+H]+.1H-NMR(400MHz,CDCl3)(ppm):7.752(d,2H),7.610(s,1H),7.549(m,2H),7.387(t,2H),7.307(m,2H),7 .042(d,1H),6.960(d,2H),5.185(s,2H),4.697(m,1H),4.444(m,1H), 4.336(m,1H),4.201(m,1H),3.483(s,3H),3.131(m,1H),3.004(m,1H).

[0061] Example 2 Synthesis of Boc-3-iodo-D-Tyr(MOM)-OH (5D) The synthesis of Boc-3-iodo-D-Tyr(MOM)-OH was carried out as described in Scheme B2: [ka] In step (a), (R)-2-amino-3-(4-hydroxy-3-iodophenyl)propionic acid 11 (also known as 3-iodo-D-tyrosine or 3-iodo-D-Tyr-OH) is reacted with di-tert-butyl dicarbonate (BocO) to give (R)-2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-3-iodophenyl)propionic acid 22 (also known as Boc-3-iodo-D-Tyrr-OH). The reaction takes place in a mixture of water, tetrahydrofuran, and triethylamine. Next, in step (b), compound 22 is reacted with methoxymethyl bromide (CH3-O-CH2-Br) to give methoxymethyl-(R)-2-((tert-butoxycarbonyl)amino)-3-(3-iodo-4-(methoxymethoxy)phenyl)propanoate 23 (also known as Boc-3-iodo-D-Tyr(MOM)-OMOM). The reaction occurs in dichloromethane (DCM) in the presence of diisopropylethylamine (DIPEA) and tetrabutylammonium chloride (TBACl). Next, in step (c), compound 23 is converted to the target compound 5D. The reaction occurs in a mixture of tetrahydrofuran (THF), water, and pyridine.

[0062] a) Synthesis of Boc-3-iodo-D-Tyr-OH (22) 3-Iodo-D-Tyr-OH 11 (16.28 mmol) was dissolved in 150 mL of a mixture of THF / HO (1:1) and TEA (4.44 mL, 32.56 mmol, 2 equiv.) was added. The mixture was cooled to 0 °C on ice. BocO (3.63 mL, 17.9 mmol, 1.1 equiv.) was dissolved in a water bath at 30 °C and then dissolved in 20 mL of THF. The solution was transferred to a dropping funnel and added dropwise over 30 min. After 1 h, the ice bath was removed, and the reaction mixture was stirred overnight at room temperature. The completeness of the conversion was checked by HPLC. THF was removed under reduced pressure. The aqueous solution was adjusted to pH 3–4 with 1 M HCl and extracted three times with 150 mL of ethyl acetate each time. The combined organic phases were dried over sodium sulfate, and the solvent was removed under reduced pressure. The product was dried under high vacuum. The purity of the synthesized product (Boc-3-iodo-D-Tyr-OH 22) was determined by HPLC (>95%).

[0063] b) Synthesis of Boc-3-iodo-D-Tyr(MOM)-OMOM (23) Boc-3-iodo-D-Tyr-OH 22 (16.28 mmol) was dissolved in 120 mL of dry DCM. DIPEA (5.67 mL, 32.56 mmol, 2 equiv.) and tetrabutylammonium chloride (0.453 g, 1.63 mmol, 0.1 equiv.) were added. A solution of methoxymethyl bromide (2.657 mL, 32.56 mmol, 2 equiv.) in 30 mL of anhydrous DCM was slowly added dropwise to the ice-cooled solution of Boc-3-iodo-D-Tyr-OH over 30 min. After 1 h, the ice bath was removed and the mixture was stirred overnight at room temperature. After addition of water, the organic phase was dried and evaporated under reduced pressure. The completeness of the conversion was checked by HPLC. The product, Boc-3-iodo-D-Tyr(MOM)-OMOM 23, was identified by HPLC (>95%).

[0064] c) Synthesis of Boc-3-iodo-D-Tyr(MOM)-OH (5D) Boc-ID-Tyr(MOM)-OMOM was dissolved in 20 mL of THF. 20 mL of 2 M aqueous LiOH was added and stirred at room temperature for 2 hours. THF was removed under reduced pressure. 300 mL of DCM and 150 mL of 5% KHSO4 solution were added and stirred for 5 minutes. After phase separation, the aqueous phase was extracted once with 150 mL of DCM. The combined organic phases were dried over Na2SO4, and the solvent was removed under reduced pressure. The resulting product was lyophilized.

[0065] 1 H-NMR(400MHz,CDCl3)δ(ppm):7.619(s,1H),7.103(d,1H),6.993(d,1H),5.216(s ,2H),4.968;4.54(m,1H),3.504(s,3H),3.138(m,1H),2.993(m,1H),1.440(s,9H).

[0066] Example 3 a) Synthesis of tripeptides Tripeptides were prepared to demonstrate the improved coupling properties of compounds of general formula IA according to the present invention. The resulting tripeptides are shown in Table 2, where Ac is acetyl, Me is methyl, Amb is aminomethylbenzoyl, and Pbf is 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl.

[0067] Tripeptides P1 and P2 according to the invention were prepared using either Fmoc-3-iodo-D-Tyr(MOM)-OH (compound 1D) or Boc-3-iodo-D-Tyr(MOM)-OH (compound 5D). Additionally, tripeptides V1 and V2 were prepared for comparison purposes. Tripeptides V1 and V2 differ from tripeptides P1 and P2 by the protection of the phenolic hydroxy group. In tripeptides P1 and P2, the phenolic hydroxy group is protected by a —CH—O—CH group (MOM), whereas in tripeptides V1 and V2, it is unprotected.

[0068] [Table 2] TIFF0007818005000034.tif218170

[0069] The tripeptides were prepared using the Fmoc / tBu strategy developed by Merrifield on a chlorotrityl resin, also known as the "Barlos resin" (Barlos, K., et al., "Peptid-Fragmente unter Einsatz substituierter Triphenylmethylharze," Tetrahedron Letters, 1989, 30(30), pp. 3943-3946). This allows for cleavage of the fully protected peptide fragment with a weakly acidic compound such as hexafluoroisopropanol (HFIP). Coupling of all amino acid-like components was carried out using diisopropylcarbodiimide (DIC) and hydroxyiminocyanoacetic acid ethyl ester (Oxyma). The Fmoc protecting group was cleaved with 20% piperidine in DMF. The peptide was cleaved from the resin with 20% 1,1,1,3,3,3-hexafluoropropan-2-ol (HFIP) in DCM.

[0070] b) Comparative test The tripeptides P1 and P2 according to the invention and the comparative tripeptides V1 and V2 were coupled within 60 minutes using diisopropylcarbodiimide (DIC) and hydroxyiminocyanoacetic acid ethyl ester (Oxyma).

[0071] Fmoc-3-iodo-d-Tyr(MOM)-OH (1D) was coupled to HN-Me-D-Orn(Amb-Ac)-Arg(Pbf)-chlorotrityl resin to produce tripeptide P1. The coupling was followed kinetically. The results are shown in Table 3.

[0072] [Table 3]

[0073] To prepare tripeptide V1, Fmoc-3-iodo-D-Tyr-OH was coupled to HN-Me-D-Orn(Amb-Ac)-Arg(Pbf)-chlorotrityl resin. The coupling was followed kinetically. The results are shown in Table 4.

[0074] [Table 4]

[0075] To prepare tripeptide P2, Boc-3-iodo-d-Tyr(MOM)-OH (5D) was coupled to HN-Me-D-Orn(Amb-Ac)-Arg(Pbf)-chlorotrityl resin. The coupling was followed kinetically. The results are shown in Table 5.

[0076] [Table 5]

[0077] To prepare tripeptide V2, Boc-3-iodo-D-Tyr-OH was coupled to HN-Me-D-Orn(Amb-Ac)-Arg(Pbf)-chlorotrityl resin. The coupling was followed kinetically. The results are shown in Table 6.

[0078] [Table 6]

[0079] In the preparation of tripeptides P1 and P2 according to the present invention, as well as tripeptides V1 and V2 used for comparison, we demonstrate that the use of both Fmoc-3-iodo-D-Tyr(MOM)-OH (1D) and Boc-3-iodo-D-Tyr(MOM)-OH (5D) affords the target compounds in high purity and yield. The use of unprotected iodo-tyrosine derivatives in the side chain resulted in significantly reduced yields and the generation of unspecified by-products. Tripeptides P1 and P2 demonstrate the improved efficiency of peptide synthesis afforded by the use of tyrosine derivatives according to the present invention bearing a protected phenolic hydroxy function.

[0080] Example 4 Synthesis of Penthixather Penthixatel was prepared very efficiently using the amino acid Fmoc-3-iodo-D-Tyr(MOM)-OH (1D), but little or no conversion was obtained using the unprotected amino acid Fmoc-3-iodo-D-Tyr-OH.

[0081] Example 5 Synthesis of PSMAI&T The synthesis of the compound Glu-CO-Lys[(Sub)DLys-DPhe-DTyr(3I)-DO-TAGA]trifluoroacetate (PSMAI&T) (Wirtz, M., et al., Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity. EJNMMI Research, 2018. 8(1): p. 84) could similarly proceed with the synthesis of Pentather, but with higher efficiency and significantly improved purity of the final product when Boc-3-iodo-D-tyrosine (MOM)-OH (1D) was used instead of the unprotected derivative.

[0082] Cited literature 1. Sadri, K., et al., Synthesis and biodistribution studies of iodine-131 D-amino acid YYK peptide as a potential therapeutic agent for labeling an anti-CD20 antibody. 2009. 52(7): p. 289-294. 2. Hallaba, E., H. El-Asrag, and Y. Abou Zeid, 131I-labelling of tyrosine by iodine monochloride. The International Journal of Applied Radiation and Isotopes, 1970. 21(2): p. 107-110. 3. Martin, E.B., et al., Evaluation of the effect of D-amino acid incorporation into amyloid-reactive peptides. Journal of translational medicine, 2017. 15(1): p. 247-247. 4. Assoian, R.K., et al., Iodotyrosylation of peptides using tertiary-butyloxycarbonyl-l-[125I]iodotyrosine N-hydroxysuccinimide ester. Analytical Biochemistry, 1980. 103(1): p. 70-76. 5. Schottelius, M., et al., [(177)Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. Theranostics, 2017. 7(9): p. 2350-2362. 6. Brogsitter, C., et al., Twins in spirit part II: DOTATATE and high-affinity DOTATATE-the clinical experience. European journal of nuclear medicine and molecular imaging, 2014. 41. 7. Weineisen, M., et al., 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J Nucl Med, 2015. 56(8): p. 1169-76. 8. A, W.M., IODINATED INSULIN ANALOGUES WITH FORESHORTENED SIGNALING. 14.12.2016. 9. Schottelius, M., et al., An optimized strategy for the mild and efficient solution phase iodination of tyrosine residues in bioactive peptides. Tetrahedron Letters, 2015. 56(47): p. 6602-6605. 10. Steer, A.M., et al., A direct route for the preparation of Fmoc / OtBu protected iodotyrosine. Tetrahedron Letters, 2018. 59(27): p. 2644-2646. 11. White, J.D. and J.C. Amedio, Total synthesis of geodiamolide A, a novel cyclodepsipeptide of marine origin. The Journal of Organic Chemistry, 1989. 54(4): p. 736-738. 12. Ishiwata, H., et al., Total Synthesis of Doliculide, a Potent Cytotoxic Cyclodepsipeptide from the Japanese Sea Hare Dolabella auricularia. The Journal of Organic Chemistry, 1994. 59(17): p. 4712-4713. 13. Pedersen, M.H.F. and L. Martiny, Homogeneous deuteriodeiodination of iodinated tyrosine in angiotensin-I using synthesized triethyl[2H]silane and Pd(0). 2011. 54(4): p. 191-195.

Claims

1. A method for producing a compound of general formula III by reacting a compound of general formula II with a compound of general formula X-A, 【Chemistry 1】 【Chemistry 2】 Further, reacting a compound of general formula III to give a compound of general formula I, wherein SG is a protecting group selected from the group consisting of a fluorenylmethyleneoxycarbonyl group (Fmoc), a tert-butoxycarbonyl group (Boc), and a benzyloxycarbonyl group; X is a halogen or ammonia; A is selected from the group consisting of unbranched or branched alkyl groups having 1 to 12 carbon atoms, -R1-O-R2-, -R1-Si(R3R4R5)-, -R1-O-Si(R3R4R5)-, -C(O)-O-R9-Si(R3R4R5)-, -CH(O-R6)(O-R7)-, -R1-CH(O-R6)(O-R7)-, -R1-O-C(O)-O-R8- groups (wherein methyl, t-butyl, and -CH2-CH=CH2 groups are excluded); R 1 is a divalent hydrocarbon group having 1 to 12 carbon atoms; R 2 is a monovalent hydrocarbon group having 1 to 12 carbon atoms; R 3 , R 4 and R 5 are each independently a monovalent hydrocarbon group having 1 to 12 carbon atoms; R 6 and R 7 are each independently a monovalent hydrocarbon group having 1 to 12 carbon atoms; R 8 is a monovalent hydrocarbon group having 1 to 12 carbon atoms; R 9 is a divalent hydrocarbon group having 1 to 12 carbon atoms; 【Transformation 3】 wherein A and SG have the meanings given in relation to formula II. A process for the preparation of compounds of general formula I, characterized in that a compound of general formula I is obtained.

2. The method of claim 1, wherein the compound of general formula I is a compound of general formula IA. 【Chemistry 4】 During the ceremony, A and SG have the meanings defined in claim 1.

3. A is an unbranched or branched alkyl group having 1 to 12 carbon atoms; １ -O-R ２ - group, -R １ -Si(R ３ R ４ R ５ )- group and —C(O)—O—R ９ -Si(R ３ R ４ R ５ )-groups, wherein R １ , R ２ , R ３ , R ４ , R ５ and R ９ 3. The method according to claim 1 or 2, characterized in that: has the meaning as defined in claim 1.

4. A is an alkyl group having 1 to 6 carbon atoms; R １ is an alkylene group having 1 to 6 carbon atoms, and R ２ is an unbranched or branched alkyl group having 1 to 6 carbon atoms; １ -O-R ２ Group; R １ is an alkylene group having 1 to 6 carbon atoms, and R ３ , R ４ and R ５ each independently represents an unbranched or branched alkyl group having 1 to 6 carbon atoms, or an aryl group; １ -Si(R ３ R ４ R ５ )-group; and R ９ is an alkylene group having 1 to 6 carbon atoms, and R ３ , R ４ and R ５ are each independently an unbranched or branched alkyl group having 1 to 6 carbon atoms, or an aryl group, ９ -Si(R ３ R ４ R ５ 4. The method according to claim 1, wherein the alkyl group is selected from the group consisting of aryl, aryl- ...

5. A is an alkyl group having 1 to 6 carbon atoms; R １ is an alkylene group having 1 to 4 carbon atoms, and R ２ is an unbranched or branched alkyl group having 1 to 6 carbon atoms; １ -O-R ２ Group; R １ is an alkylene group having 1 to 4 carbon atoms, and R ３ , R ４ and R ５ each independently represents an unbranched or branched alkyl group having 1 to 6 carbon atoms, or an aryl group; １ -Si(R ３ R ４ R ５ )-group; and R ９ is an alkylene group having 1 to 6 carbon atoms, and R ３ , R ４ and R ５ are each independently an unbranched or branched alkyl group having 1 to 6 carbon atoms, or an aryl group, ９ -Si(R ３ R ４ R ５ 5. The method according to claim 1, wherein the alkyl group is selected from the group consisting of aryl, aryl, aryl- ...

6. The compound of general formula I, 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-iodo-4-(methoxymethoxy)phenyl)propionic acid 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-iodo-4-(((2-(trimethylsilyl)ethoxy)carbonyl)oxy)phenyl)propionic acid, 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(2-(tert-butyldiphenylsilyl)ethoxy)-3-iodophenyl)propionic acid, or The method according to any one of claims 1 to 5, characterized in that the compound is 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(tert-butoxy)-3-iodophenyl)propionic acid.

7. The compound of general formula I 2-((tert-butoxycarbonyl)amino)-3-(3-iodo-4-(methoxymethoxy)phenyl)propionic acid, 2-((tert-butoxycarbonyl)amino)-3-(3-iodo-4-(((2-(trimethylsilyl)ethoxy)carbonyl)oxy)phenyl)propionic acid, 2-((tert-butoxycarbonyl)amino)-3-(4-(2-(tert-butyldiphenylsilyl)ethoxy)-3-iodophenyl)propionic acid, or The method according to any one of claims 1 to 5, characterized in that the compound is 2-((tert-butoxycarbonyl)amino)-3-(4-(tert-butoxy)-3-iodophenyl)propionic acid.

8. Compounds of general formula II can be prepared from compounds of general formula IV 【Transformation 5】 The method according to any one of claims 1 to 7, characterized in that the compound is produced by introducing a protecting group SG onto the amino group of the compound of general formula IV.

Images